Potential therapeutic approaches in paraquat poisoning: a narrative review

Author(s):  
Amir Ghabousian ◽  
Saeed Safari ◽  
Niloufar Ansari

Paraquat dichloride (PQ) poisoning is a relatively rare yet critical medical condition that has a high case fatality rate. Lung tissue is highly susceptible to PQ-induced injury, and respiratory failure is the leading cause of death in these patients. Unfortunately, there is a lack of an effective therapeutic approach to ameliorate outcomes. It is well-known that PQ interferes with a variety of cell signaling pathways and induces the generation of reactive oxygen species (ROS), which ultimately results in cell injury. The traditional treatment decisions have not been able to significantly change the clinical course of PQ poisoning. Moreover, novel therapeutic strategies for PQ poisoning have centered on the inhibition of PQ-induced signaling pathways. In the current review, we sought to provide a bird’s-eye view of the available therapeutic approaches in patients with PQ poisoning.

Author(s):  
Shaoli De ◽  
Agraharam Gopikrishna ◽  
Vedhantham Keerthana ◽  
Agnishwar Girigoswami ◽  
Koyeli Girigoswami

Background: Economic development and vast changes in food habits have accelerated the consumption of junk foods which are the leading causes of several disorders that turns majority of the people to use various herbal formulations or drugs for preventing various lifestyle diseases. Nutraceuticals are the borderline apparatus between nutrients and drugs that provides supplementation of particular nutrient with favorable health effect. Objective: Various nutraceutical compounds like vitamins, spices, polyphenols, prebiotics and probiotics in the form of powders, tablets, capsules are currently marketed globally. Among them previous literatures have reported that polyphenols are the most promising compounds that have been proven to treat various chronic diseases like cancer, hypertension, diabetes mellitus (DM), osteoporosis, osteoarthritis, dyslipidemia, multiple sclerosis, congenital anomalies, Alzheimer’s disease, etc. It is warranted to discuss about the benefits of nanoformulations of nutraceuticals. Methods: We have searched PubMed using the keywords nutraceuticals, nanoformulations, therapeutic approaches, bionanotechnology, and therapeutics. The relevant papers and classical papers in this field were selected to write this review. Results and Discussion: The different classifications of nutraceuticals were elaborately described in this review. The comparison between the different categories of nutraceuticals with their nanoformulated forms was done explaining the benefits of nanoformulations regarding stability, bioavailability, enhanced antioxidant properties etc. A glimpse on the drawbacks of nanoformulations were also included. Conclusion: The current review highlights an overview of various nanoformulated nutraceuticals and its approach towards the treatment of multiple diseases.


2021 ◽  
Vol 22 (7) ◽  
pp. 3682
Author(s):  
Dorota Gil ◽  
Piotr Laidler ◽  
Marta Zarzycka ◽  
Joanna Dulińska-Litewka

The twofold role of autophagy in cancer is often the therapeutic target. Numerous regulatory pathways are shared between autophagy and other molecular processes needed in tumorigenesis, such as translation or survival signaling. Thus, we have assumed that ILK knockdown should promote autophagy, and used together with chloroquine, an autophagy inhibitor, it could generate a better anticancer effect by dysregulation of common signaling pathways. Expression at the protein level was analyzed using Western Blot; siRNA transfection was done for ILK. Analysis of cell signaling pathways was monitored with phospho-specific antibodies. Melanoma cell proliferation was assessed with the crystal violet test, and migration was evaluated by scratch wound healing assays. Autophagy was monitored by the accumulation of its marker, LC3-II. Our data show that ILK knockdown by siRNA suppresses melanoma cell growth by inducing autophagy through AMPK activation, and simultaneously initiates apoptosis. We demonstrated that combinatorial treatment of melanoma cells with CQ and siILK has a stronger antitumor effect than monotherapy with either of these. It generates the synergistic antitumor effects by the decrease of translation of both global and oncogenic proteins synthesis. In our work, we point to the crosstalk between translation and autophagy regulation.


2021 ◽  
Vol 160 ◽  
pp. 103277
Author(s):  
Ana Carolina B. da C. Rodrigues ◽  
Rafaela G.A. Costa ◽  
Suellen L.R. Silva ◽  
Ingrid R.S.B. Dias ◽  
Rosane B. Dias ◽  
...  

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S332-S332
Author(s):  
Anna Hardesty ◽  
Aakriti Pandita ◽  
Yiyun Shi ◽  
Kendra Vieira ◽  
Ralph Rogers ◽  
...  

Abstract Background Organ transplant recipients (OTR) are considered high-risk for morbidity and mortality from COVID-19. Case-fatality rates (CFR) vary significantly in different case series, and some patients were still hospitalized at the time of analyses. To our knowledge, no case-control study of COVID-19 in OTR has been published to-date. Methods We captured kidney transplant recipients (KTR) diagnosed with COVID-19 between 3/1 and 5/18/2020. After exclusion of KTR on hemodialysis and off immunosuppression (IS), we compared the clinical course of COVID-19 between hospitalized KTR and non-transplant patients, matched by sex and age (controls). All patients were discharged from the hospital or died. Results 16 KTR had COVID-19. All 3 KTR off IS, who were excluded from further analyses, survived. Median age was 54 (range: 34–65) years; 5/13 KTR (38.4%) were men. Median time from transplant was 41 (range: 1–203) months. Two KTR, both transplanted >10 years ago, were managed as outpatients. IS was reduced in 12/13 (92.3%), most often by discontinuation of the antimetabolite. IL6 levels were >1,000 (normal: < 5) pg/mL in 3 KTR. Tacrolimus or sirolimus levels were >10 ng/mL in 6/9 KTR (67%) (Table 1). Eleven KTR were hospitalized (84.6%) and matched with 44 controls. One KTR, the only one treated with hydroxychloroquine, died (CFR 5.8%; 7.6% in KTR on IS; 9% in hospitalized KTR on IS). Four controls died (CFR: 9%; state CFR: 5.2%; inpatient CFR: 16.6%). There were no significant differences in length of stay or worst oxygenation status between hospitalized KTR and controls. Four KTR (30.7%), received remdesivir, 4 convalescent plasma, 3 (23%) tocilizumab. KTR received more often broad-spectrum antibiotics, convalescent plasma or tocilizumab, compared to controls (Table 2). Table 1 Table 2 Conclusion Unlike early reports from the pandemic epicenters, the clinical course and outcomes of KTR with COVID-19 in our small case series were comparable to those of non-transplant patients. Calcineurin or mTOR inhibitor levels were high, likely due to diarrhea and COVID-19-related hepatic dysfunction. Extremely high IL6 levels were common. The role of IS and potential benefits from investigational treatments remain to be elucidated. A larger multi-institutional study is underway. Disclosures All Authors: No reported disclosures


Author(s):  
Ibrahim Jantan ◽  
Md. Areeful Haque ◽  
Laiba Arshad ◽  
Hemavathy Harikrishnan ◽  
Abdi Wira Septama ◽  
...  

2007 ◽  
Vol 50 (8) ◽  
pp. 1230-1240 ◽  
Author(s):  
Maren K. Fuentes ◽  
Shraddha S. Nigavekar ◽  
Thiruvengadam Arumugam ◽  
Craig D. Logsdon ◽  
Ann Marie Schmidt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document